{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:59:12Z","timestamp":1783479552785,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.diabres.2020.108337","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T11:13:19Z","timestamp":1595329999000},"page":"108337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy"],"prefix":"10.1016","volume":"166","author":[{"given":"Anna","family":"Kloska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Korzon-Burakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelina","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Bruhn-Olszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Gabig-Cimi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Jak\u00f3bkiewicz-Banecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2020.108337_b0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2020.108337_b0010","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2337\/dc05-2228","article-title":"The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes","volume":"29","author":"Davies","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000092180","article-title":"The prevalence of neuropathy and relationship with risk factors in diabetic patients: a single-center experience","volume":"15","author":"Tamer","year":"2006","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.diabres.2020.108337_b0020","series-title":"Atlas Diabet. Foot","first-page":"147","article-title":"Charcot Foot","author":"Makrilakis","year":"2019"},{"key":"10.1016\/j.diabres.2020.108337_b0025","series-title":"Diabetic Foot Syndrome: From Entity to Therapy","first-page":"335","author":"Hochlenert","year":"2018"},{"key":"10.1016\/j.diabres.2020.108337_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060917","article-title":"Neuropathy and Diabetic Foot Syndrome","volume":"17","author":"Volmer-Thole","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2020.108337_b0035","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2337\/dc11-0844","article-title":"The Charcot foot in diabetes","volume":"34","author":"Rogers","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4239\/wjd.v2.i5.59","article-title":"Charcot osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice","volume":"2","author":"Gouveri","year":"2011","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabres.2020.108337_b0045","first-page":"372","article-title":"arthritide symptomatica of William Musgrave (1657\u20131721): His description of neuropathic arthritis","volume":"37","author":"De","year":"1963","journal-title":"Bull Hist Med"},{"key":"10.1016\/j.diabres.2020.108337_b0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000441-183108150-00004","article-title":"On a new practice in acute and chronic rheumatism","volume":"8","author":"Mitchell","year":"1831","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.diabres.2020.108337_b0055","first-page":"161","article-title":"Sur quelques arthropathies qui paraissent d\u00e9pendre d\u2019une l\u00e9sion du cerveau ou de la moelle \u00e9pini\u00e8re","author":"Charcot","year":"1868","journal-title":"Arch. Physiol. Norm. Pathol., V. Masson"},{"key":"10.1016\/j.diabres.2020.108337_b0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archinte.1936.00170060069004","article-title":"Neuritic Manifestations in Diabetes Mellitus","volume":"57","author":"Jordan","year":"1936","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabres.2020.108337_b0065","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7547\/87507315-92-7-390","article-title":"Charcot\u2019s arthropathy of the foot","volume":"92","author":"Armstrong","year":"2002","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.diabres.2020.108337_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cpm.2007.10.001","article-title":"Epidemiology of the Charcot foot","volume":"25","author":"Frykberg","year":"2008","journal-title":"Clin Podiatr Med Surg"},{"key":"10.1016\/j.diabres.2020.108337_b0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/ijem.IJEM_257_17","article-title":"Prevalence of Charcot Arthropathy in Type 2 Diabetes Patients Aged over 50 Years with Severe Peripheral Neuropathy: A Retrospective Study in a Tertiary Care South Indian Hospital","volume":"22","author":"Salini","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.diabres.2020.108337_b0080","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2106\/00004623-198870080-00010","article-title":"Fractures associated with neuropathic arthropathy in adults who have juvenile-onset diabetes","volume":"70","author":"Clohisy","year":"1988","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.diabres.2020.108337_b0085","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2337\/dc08-1695","article-title":"Mortality risk of Charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone","volume":"32","author":"Sohn","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00125-002-0885-7","article-title":"Charcot neuroarthropathy in diabetes mellitus","volume":"45","author":"Rajbhandari","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2020.108337_b0095","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/diacare.27.5.1235-a","article-title":"Difference in presentation of Charcot osteoarthropathy in type 1 compared with type 2 diabetes","volume":"27","author":"Petrova","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1590\/2359-3997000000042","article-title":"Risk factors for Charcot foot","volume":"59","author":"Nobrega","year":"2015","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.diabres.2020.108337_b0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.amjmed.2008.06.038","article-title":"Charcot arthropathy risk elevation in the obese diabetic population","volume":"121","author":"Stuck","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2020.108337_b0110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/107110070502600506","article-title":"The association between body mass index and foot disorders in diabetic patients","volume":"26","author":"Pinzur","year":"2005","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.diabres.2020.108337_b0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.jfas.2012.10.003","article-title":"Role of body mass index in acute charcot neuroarthropathy","volume":"52","author":"Ross","year":"2013","journal-title":"J Foot Ankle Surg"},{"key":"10.1016\/j.diabres.2020.108337_b0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7547\/1020213","article-title":"Peripheral and central bone mineral density in Charcot\u2019s neuroarthropathy compared in diabetic and nondiabetic populations","volume":"102","author":"Greenhagen","year":"2012","journal-title":"J Am Podiatr Med Assoc"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2020.108337_b0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1755-6686.2012.00284.x","article-title":"Foot problems in patients with diabetes and chronic kidney disease","volume":"38","author":"Valabhji","year":"2012","journal-title":"J Ren Care"},{"key":"10.1016\/j.diabres.2020.108337_b0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.jfas.2018.09.022","article-title":"Development of Charcot Neuroarthropathy in Diabetic Patients who Received Kidney or Kidney-Pancreas Transplants","volume":"58","author":"Anthony","year":"2019","journal-title":"J Foot Ankle Surg"},{"key":"10.1016\/j.diabres.2020.108337_b0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.tp.0000244730.95416.c6","article-title":"High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation","volume":"83","author":"Matricali","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.diabres.2020.108337_b0140","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1055\/s-2006-924229","article-title":"Evaluation of the diabetic charcot foot by MR imaging or plain radiography-an observational study","volume":"114","author":"Chantelau","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.diabres.2020.108337_b0145","first-page":"9","article-title":"Imaging osteomyelitis and the diabetic foot","volume":"43","author":"Becker","year":"1999","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.diabres.2020.108337_b0150","series-title":"The Diabetic Charcot Foot: Principles and Management","first-page":"65","article-title":"Imaging of the Charcot foot","author":"Morrison","year":"2010"},{"key":"10.1016\/j.diabres.2020.108337_b0155","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/107110079902000905","article-title":"Benchmark analysis of diabetic patients with neuropathic (Charcot) foot deformity","volume":"20","author":"Pinzur","year":"1999","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.diabres.2020.108337_b0160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.17161\/kjm.v11i4.8709","article-title":"Initial Diagnosis and Management for Acute Charcot Neuroarthropathy","volume":"11","author":"Vopat","year":"2018","journal-title":"Kansas J Med"},{"key":"10.1016\/j.diabres.2020.108337_b0165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.7547\/87507315-92-7-384","article-title":"From acute to chronic: monitoring the progress of Charcot\u2019s arthropathy","volume":"92","author":"Nube","year":"2002","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.diabres.2020.108337_b0170","first-page":"37","article-title":"Pro-Calcitonin, Erythrocyte Sedimentation Rate and C - reactive Protein in Predicting Diabetic Foot Ulcer Characteristics; a Cross Sectional Study","volume":"7","author":"Hadavand","year":"2019","journal-title":"Arch Acad Emerg Med"},{"key":"10.1016\/j.diabres.2020.108337_b0175","series-title":"The Diabetic Charcot Foot: Principles and Management","first-page":"93","article-title":"Principles of conservative management","author":"Frykberg","year":"2010"},{"key":"10.1016\/j.diabres.2020.108337_b0180","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7547\/87507315-87-6-272","article-title":"The natural history of acute Charcot\u2019s arthropathy in a diabetic foot specialty clinic","volume":"87","author":"Armstrong","year":"1997","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.diabres.2020.108337_b0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cpm.2016.07.003","article-title":"Conservative and Pharmacologic Treatments for the Diabetic Charcot Foot","volume":"34","author":"Petrova","year":"2017","journal-title":"Clin Podiatr Med Surg"},{"key":"10.1016\/j.diabres.2020.108337_b0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1071100717742371","article-title":"Deformity and Clinical Outcomes Following Operative Correction of Charcot Foot: A New Classification With Implications for Treatment","volume":"39","author":"Pinzur","year":"2018","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.diabres.2020.108337_b0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1071100718805076","article-title":"Deformity and Clinical Outcomes Following Operative Correction of Charcot Ankle","volume":"40","author":"Harkin","year":"2019","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.diabres.2020.108337_b0200","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1573399815666190502121945","article-title":"Charcot Neuroarthropathy: From the Laboratory to the Bedside","volume":"16","author":"Pitocco","year":"2019","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.diabres.2020.108337_b0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-2006-944525","article-title":"Charcot foot in diabetes: farewell to the neurotrophic theory","volume":"38","author":"Chantelau","year":"2006","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabres.2020.108337_b0210","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1464-5491.2005.01510.x","article-title":"Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes","volume":"22","author":"Petrova","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2020.108337_b0215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2522\/ptj.20080025","article-title":"Inflammatory osteolysis in diabetic neuropathic (charcot) arthropathies of the foot","volume":"88","author":"Sinacore","year":"2008","journal-title":"Phys Ther"},{"key":"10.1016\/j.diabres.2020.108337_b0220","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1475-097X.2009.00915.x","article-title":"Bone mineral density in diabetes mellitus patients with and without a Charcot foot","volume":"30","author":"Christensen","year":"2010","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.diabres.2020.108337_b0225","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc10-0636","article-title":"A prospective study of calcaneal bone mineral density in acute Charcot osteoarthropathy","volume":"33","author":"Petrova","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdiacomp.2017.11.004","article-title":"Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study","volume":"32","author":"Jansen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2020.108337_b0235","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.fas.2012.12.007","article-title":"Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial","volume":"19","author":"Pakarinen","year":"2013","journal-title":"Foot Ankle Surg"},{"key":"10.1016\/j.diabres.2020.108337_b0240","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/S0140-6736(05)67029-8","article-title":"The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes","volume":"366","author":"Jeffcoate","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2020.108337_b0245","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/107110070602701007","article-title":"Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study","volume":"27","author":"Baumhauer","year":"2006","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.diabres.2020.108337_b0250","doi-asserted-by":"crossref","first-page":"5647981","DOI":"10.1155\/2018\/5647981","article-title":"Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot","volume":"2018","author":"Jansen","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.diabres.2020.108337_b0255","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/dme.12590","article-title":"Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy","volume":"32","author":"Petrova","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2020.108337_b0260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13047-015-0096-3","article-title":"IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study","volume":"8","author":"Folestad","year":"2015","journal-title":"J Foot Ankle Res"},{"key":"10.1016\/j.diabres.2020.108337_b0265","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13047-015-0129-y","article-title":"Offloading treatment is linked to activation of proinflammatory cytokines and start of bone repair and remodeling in Charcot arthropathy patients","volume":"8","author":"Folestad","year":"2015","journal-title":"J Foot Ankle Res"},{"key":"10.1016\/j.diabres.2020.108337_b0270","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabres.2020.108337_b0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabres.2020.108337_b0280","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/endo.142.4.8070","article-title":"Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus","volume":"142","author":"Ikeda","year":"2001","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2020.108337_b0285","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.diabres.2020.108337_b0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1365.035","article-title":"Bone remodeling","volume":"1092","author":"Hadjidakis","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.diabres.2020.108337_b0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/02841860600635870","article-title":"Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)\/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton","volume":"46","author":"Mountzios","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.diabres.2020.108337_b0300","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S8756-3282(00)00411-7","article-title":"Evaluation of the role of RANK and OPG genes in Paget\u2019s disease of bone","volume":"28","author":"Wuyts","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.diabres.2020.108337_b0305","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/art.21896","article-title":"The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction","volume":"54","author":"Geusens","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.diabres.2020.108337_b0310","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2020.108337_b0315","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2337\/db10-1220","article-title":"The RANKL\/RANK\/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy","volume":"60","author":"Ndip","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2020.108337_b0320","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00198-013-2511-6","article-title":"Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy","volume":"25","author":"Petrova","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.diabres.2020.108337_b0325","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11892-005-0050-z","article-title":"Theories concerning the pathogenesis of the acute charcot foot suggest future therapy","volume":"5","author":"Jeffcoate","year":"2005","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2020.108337_b0330","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00125-014-3348-z","article-title":"RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy","volume":"57","author":"Ndip","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2020.108337_b0335","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13018-017-0634-8","article-title":"Pathogenesis and potential relative risk factors of diabetic neuropathic osteoarthropathy","volume":"12","author":"Zhao","year":"2017","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.diabres.2020.108337_b0340","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2337\/dc10-2315","article-title":"Loss of RAGE defense: a cause of Charcot neuroarthropathy?","volume":"34","author":"Witzke","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0345","first-page":"6605","article-title":"TNFalpha and RANKL promote osteoclastogenesis by upregulating RANK via the NFkappaB pathway","volume":"17","author":"Luo","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.diabres.2020.108337_b0350","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1359\/jbmr.2002.17.7.1245","article-title":"Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures","volume":"17","author":"Langdahl","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.diabres.2020.108337_b0355","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11033-009-9637-9","article-title":"Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis","volume":"37","author":"Lee","year":"2010","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.diabres.2020.108337_b0360","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/jbmr.78","article-title":"Genetic variation in the RANKL\/RANK\/OPG signaling pathway is associated with bone turnover and bone mineral density in men","volume":"25","author":"Roshandel","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.diabres.2020.108337_b0365","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2337\/dc09-0243","article-title":"Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic charcot neuroarthropathy: a case-control study","volume":"32","author":"Pitocco","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0370","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41598-017-00563-4","article-title":"Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development","volume":"7","author":"Bruhn-Olszewska","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2020.108337_b0375","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1464-5491.2011.03442.x","article-title":"Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy","volume":"29","author":"Korzon-Burakowska","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2020.108337_b0380","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00125-008-0992-1","article-title":"Increased osteoclastic activity in acute Charcot\u2019s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand","volume":"51","author":"Mabilleau","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2020.108337_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/917945","article-title":"Inhibition of TNF- \u03b1 Reverses the Pathological Resorption Pit Profile of Osteoclasts from Patients with Acute Charcot Osteoarthropathy","volume":"2015","author":"Petrova","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.diabres.2020.108337_b0390","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2337\/dc09-1141","article-title":"Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot","volume":"33","author":"Uccioli","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108337_b0395","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2217\/epi-2018-0144","article-title":"Whole-methylome analysis of circulating monocytes in acute diabetic Charcot foot reveals differentially methylated genes involved in the formation of osteoclasts","volume":"11","author":"Pasquier","year":"2019","journal-title":"Epigenomics"},{"key":"10.1016\/j.diabres.2020.108337_b0400","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/aps.2013.188","article-title":"Microvesicles and diabetic complications\u2013novel mediators, potential biomarkers and therapeutic targets","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.diabres.2020.108337_b0405","doi-asserted-by":"crossref","first-page":"16450","DOI":"10.1038\/s41598-017-16365-7","article-title":"Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclast cell induction","volume":"7","author":"Pasquier","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2020.108337_b0410","first-page":"175","article-title":"Extracellular\/Circulating MicroRNAs: Release Mechanisms","volume":"10","author":"Sohel","year":"2016","journal-title":"Functions and Challenges. Achiev Life Sci"},{"key":"10.1016\/j.diabres.2020.108337_b0415","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2217\/epi-2018-0052","article-title":"Differentially expressed circulating microRNAs in the development of acute diabetic Charcot foot","volume":"10","author":"Pasquier","year":"2018","journal-title":"Epigenomics"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720305891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720305891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:15:59Z","timestamp":1759173359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720305891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":83,"alternative-id":["S0168822720305891"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108337","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108337"}}